In this rapidly evolving setting, clinicians are weighing the alleged harm of continuing these medications in patients for whom ACE inhibitors and ARBs have known benefit against the harm to their ...

Global trends predict a steady rise in cardiovascular disease in the next decade, and by 2020 coronary heart disease is predicted to be the leading cause of death worldwide. 1 Although lifestyle is ...

In a meta-analysis of 33 randomized controlled trials, Makani and colleagues 1 compared efficacy and safety outcomes in patients treated by blockade of the renin–angiotensin–aldosterone system (RAAS) ...

In a recent study posted to the medRxiv* preprint server, researchers conducted an umbrella review and meta-analysis of the renin-angiotensin-aldosterone system (RAAS) inhibitors' impact on ...

An aldosterone antagonist (AA) should be the drug of choice when adding a second renin-angiotensin-aldosterone system (RAAS) blocker to ACE inhibitors in patients with symptomatic systolic HF despite ...

AbstractPulmonary arterial hypertension (PAH) is associated with aberrant pulmonary vascular remodeling that leads to increased pulmonary artery pressure, pulmonary vascular resistance, and right ...

Utility of the Breast Cancer Index (BCI) in the clinical practice. CD205, a target antigen for a novel ADC: Evaluation of antigen expression on TNBC, pancreatic adenocarcinoma and bladder urothelial ...

Key parameters that influence surgical strategy in localised kidney cancer. Association of ACEI/ARB with tumor regression.

Angiotensin II receptor antagonists are agents used to modify the renin-angiotensin-aldosterone system (RAAS) through blocking angiotensin receptors. This has the effect of lowering blood pressure.

Studies in animals have shown that ACE2 is used by coronaviruses as a functional receptor. ARBs and ACE inhibitors increase the expression of ACE2; a hypothesis that their use may modify ...